OFFICIALS AT THE FEDERAL CENTERS FOR MEDICARE & MEDICAID SERVICES are at what may be the most important crossroads in the history of clinical laboratory regulation since Congress passed the CLIA 1988 legislation. Will CMS pursue the severe sanctions it disclosed to Theranos, Inc., and force the lab to close? Or will it soften its
Why Theranos Is a Big Test for CMS and CLIA
By R. Lewis Dark, from the Volume XXIII, No. 8 – June 13, 2016 issue